| Literature DB >> 25452595 |
Kathryn A Harris1, Anthony Underwood2, Dervla T D Kenna3, Anthony Brooks4, Ema Kavaliunaite5, Georgia Kapatai2, Rediat Tewolde2, Paul Aurora5, Garth Dixon1.
Abstract
BACKGROUND: Mycobacterium abscessus has emerged as a major pathogen in cystic fibrosis (CF) patients and has been associated with poor clinical outcomes, particularly following lung transplant. We investigated the acquisition of this bacterium in a cohort of pediatric CF patients.Entities:
Keywords: Mycobacterium abscessus; VNTR; cross-transmission; cystic fibrosis; whole-genome sequencing
Mesh:
Year: 2014 PMID: 25452595 PMCID: PMC4357290 DOI: 10.1093/cid/ciu967
Source DB: PubMed Journal: Clin Infect Dis ISSN: 1058-4838 Impact factor: 9.079
Twenty Patients With Cystic Fibrosis From Whom Mycobacterium abscessus Was Isolated
| Patient | Subspecies | VNTR Cluster | Sex | CF Genotype | Clinical Diagnosis of NTM Infection | Proportion of Sputum/BAL AAFB Positive | No. of Positive | Specific | Age at First | Years Between First | Infection Status at First Contact to GOSH | Main CF Attending Center/Main CF Center | UK Residence HPU |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | ABS | VNTR I | F | p.Phe508del/p.Phe508del | Likely | 6/32 | 6 | Y | 13.59 | 0 | Already Infected | South of England | Surrey and Sussex |
| 8 | ABS | VNTR I | M | p.Phe508del/p.Phe508del | Likely | 7/20 | 10 | Y | 10.29 | 10.04 | Naive | Study center | South Midlands and Hertfordshire |
| 9 | ABS | VNTR I | F | p.Phe508del/p.Trp1089X | Likely | 22/35 | 20 | Y | 10.93 | 0 | Already Infected | London (other)/study center | Northwest London |
| 10 | ABS | VNTR I | M | p.Phe508del/p.Phe508del | Likely | 5/17 | 6 | Y | 13.36 | 4.97 | Naive | Study center | South Midlands and Hertfordshire |
| 21 | ABS | VNTR I | M | p.Phe508del/p.Phe508del | Likely | 4/5 | 5 | Y | 15.15 | 11.97 | Naive | Study center | South Midlands and Hertfordshire |
| 3 | ABS | VNTR II | F | p.Phe508del/p.Phe508del | Likely | 6/25 | 11 | Y | 11.33 | 0 | Already Infected | North of England | Cumbria and Lancashire |
| 18 | ABS | VNTR II | M | p.Phe508del/p.Gly551Asp | Likely | 53/62 | 40 | Y | 5.90 | 3.79 | Naive | Study center | Northwest London |
| 19 | ABS | VNTR II | F | p.Phe508del/p.Phe508del | Likely | 0/4 | 1 | Y | 17.25 | 16.18 | Naive | Study center | Northwest London |
| 22 | ABS | VNTR II | F | Delta F508/I507/Delta F508/I507 | Likely | 5/25 | 10 | Y | 15.05 | 14.24 | Naive | Study center | Northwest London |
| 11 | ABS | Unique | F | c.2988+1G>A/p.Tyr913X | Likely | 0/40 | 3 | Y | 13.76 | 13.04 | Naive | Study center | Northeast and North- central London |
| 15 | ABS | Unique | F | p.Phe508del/c.1585–1G>A | Unlikely | 4/6 | 5 | N | 10.99 | 10.87 | Naive | Study center | Anglia |
| 17 | ABS | Unique | M | p.Phe508del/p.Phe508del | Unlikely | 1/13 | 1 | No | 14.07 | 13.81 | Naive | Study center | Southeast London |
| 24 | ABS | Unique | F | UK | Likely | 1/15 | 1 | Y | 13.27 | 0 | Already Infected | London (other) | South Midlands and Hertfordshire |
| 27 | ABS | Unique | F | p.Phe508del/p.Phe508del | Likely | 2/21 | 2 | Y | 14.86 | 5.37 | Naive | Study center | South Midlands and Hertfordshire |
| 30 | ABS | Unique | F | p.Phe508del/p.Phe508del | Likely | 3/10 | 4 | Y | 14.99 | 14.64 | Naive | Study center | Essex |
| 7 | MAS | VNTR III | F | p.Phe508del/p.Phe508del | Likely | 3/3 | 3 | Y | 14.49 | 0 | Already Infected | Midlands | West Midlands West |
| 23 | MAS | VNTR III | F | p.Phe508del/p.Phe508del | Likely | 25/40 | 30 | Y | 6.97 | 5.64 | Naive | Study center | South Midlands and Hertfordshire |
| 14 | MAS | Unique | F | p.Gly551Asp/c.2052delA | Likely | 0/8 | 1 | Y | 14.29 | 0 | Already Infected | Wales | South Wales |
| 28 | MAS | Unique | F | p.Phe508del/p.Phe508del | Likely | 1 | 1 | Y | 14.09 | 0 | Already Infected | Midlands | West Midlands East |
| 1 | BOL | Unique | F | p.Phe508del/p.Phe508del | Likely | 1/14 | 1 | Y | 10.08 | 0 | Already Infected | London (other) | Northeast and North-central London |
Clinical and radiological diagnosis of likely NTM infection with clinician decision to treat with long-term antibiotics considered active against M. abscessus was recorded in patient records.
Abbreviations: AAFB, acid-alcohol fast bacilli; ABS, Mycobacterium abscessus subsp abscessus; BAL, bronchoalveolar lavage; BOL, Mycobacterium abscessus subsp bolletii; CF, cystic fibrosis; GOSH, Great Ormond Street Hospital; HPU, Health Protection Unit; MAS, Mycobacterium abscessus subsp massiliense; NTM, nontuberculous mycobacteria; VNTR, variable-number tandem repeat.
Figure 1.Comparison of age of acquisition of Pseudomonas aeruginosa and Mycobacterium abscessus in cohort of pediatric cystic fibrosis patients. A, Age at first acquisition of P. aeruginosa in M. abscessus–negative patients (n = 122) vs age of acquisition of M. abscessus (P < .0001, Mann–Whitney U test). B, Age of acquisition of P. aeruginosa vs acquisition of M. abscessus in all 12 patients who acquired M. abscessus after first contact with hospital (P = .001, Wilcoxon signed-rank test). C, Time in years after first contact with hospital and first acquisition of P. aeruginosa vs acquisition of M. abscessus (n = 12; P = .002, Wilcoxon signed-rank test).
Figure 2.Exposure of patients who first acquired Mycobacterium abscessus after contact with our center to other M. abscessus-infected patients. Exposure of patients who acquired M. abscessus subsp abscessus (MA) variable-number tandem repeat (VNTR) I (n = 3; A and D), MA VNTR II (n = 3; C and E), and MA VNTR unique strains (n = 5; C and F) to other patients already infected with MA VNTR I, VNTR II, VNTR unique, and M. abscessus subsp massiliense strains. A–C, Total number of bed-days on the same ward at the same time that each patient was with other M. abscessus-infected patients. C–E, Total number of outpatient episodes where patients were with other M. abscessus-infected patients. Abbreviation: OPD, outpatients department.
Figure 3.A maximum likelihood tree based on single-nucleotide polymorphisms in shared regions from the whole genome of Mycobacterium abscessus isolates from this study (dark blue text) and from the study described by Bryant et al [10] (black text). Three major lineages representing the M. abscessus subsp massiliense, bolletti, and abscessus are shaded in orange, blue, and green, respectively. The scale bar represents the number of substitutions per site across 133 683 variable sites.
Figure 4.Subtrees from the maximum likelihood tree in Figure 3 representing detailed views of 4 clades where >2 isolates from this study were clustered. Where there are groups of isolates only from the study by Bryant et al [10], these are collapsed and displayed as triangles because they do not represent new data. Isolates from this study are shown in dark blue, and those from the study described by Bryant et al in black. The scale bar represents the number of substitutions per site.
Genotypic Data for All 27 Mycobacterium abscessus Isolates in This Study
| Isolate | Date Isolated | Subspecies | VNTR Profile | MLST Type | Sequence Clade | Predicted Macrolide Resistance Phenotype | ||
|---|---|---|---|---|---|---|---|---|
| 15–313 | Jun 2006 | ABS | Unique | ST-122 | 3 | T28C | None | Susceptible |
| 24–878 | Mar 2009 | ABS | Unique | Novel allele | None | none | None | Inducible resistance |
| 17–257 | Apr 2009 | ABS | Unique | Novel ST | 3 | T28C | None | Susceptible |
| 27–313 | Dec 2012 | ABS | Unique | ST-33 | Not availablea | none | None | Inducible resistance |
| 30–578 | Jun 2012 | ABS | Unique | Novel ST | None | none | None | Inducible resistance |
| 11–067 | Oct 2008 | MAS | Unique | ST-117 | None | Trunc158–430 | None | Susceptible |
| 11–618 | May 2012 | ABS | Unique | Novel allele | None | None | None | Inducible resistance |
| 2–520 | Jan 2009 | ABS | VNTR I | ST-26 | 4 | None | None | Inducible resistance |
| 8–046 | Jun 2007 | ABS | Unique | Novel ST | None | T28C | None | Susceptible |
| 8–170 | Oct 2009 | ABS | VNTR I | ST-26 | 4 | None | None | Inducible resistance |
| 8–768 | May 2012 | ABS | VNTR I | ST-26 | 4 | None | None | Inducible resistance |
| 9–847 | Nov 2009 | ABS | VNTR I | ST-26 | 4 | None | None | Inducible resistance |
| 21–468 | Oct 2009 | ABS | VNTR I | ST-26 | 4 | None | None | Inducible resistance |
| 10–994 | Feb 2011 | ABS | VNTR I | ST-26 | 4 | None | None | Inducible resistance |
| 18–169 | Jun 2007 | ABS | VNTR II | ST-1 | 2 | None | None | Inducible resistance |
| 18–114 | Mar 2008 | ABS | VNTR II | ST-1 | 2 | None | None | Inducible resistance |
| 18–362 | Mar 2010 | ABS | VNTR II | ST-1 | 2 | None | None | Inducible resistance |
| 18–531 | Jan 2012 | ABS | VNTR II | ST-1 | 2 | None | None | Inducible resistance |
| 3–390 | Jul 2009 | ABS | VNTR II | ST-1 | 2 | None | None | Inducible resistance |
| 22–071 | Feb 2009 | ABS | VNTR II | ST-1 | 2 | None | None | Inducible resistance |
| 19–825 | Jun 2007 | ABS | VNTR II | ST-1 | 2 | None | None | Inducible resistance |
| 14–907 | Apr 2005 | MAS | Unique | ST-69 | None | Trunc158–430 | None | Susceptible |
| 7–983 | Apr 2009 | MAS | VNTR III | ST-23 | 1 | Trunc158–430 | None | Susceptible |
| 23–476 | Feb 2009 | MAS | VNTR III | ST-48 | None | Trunc158–430 | None | Susceptible |
| 23–816 | Nov 2011 | MAS | VNTR III | ST-48 | None | Trunc158–430 | None | Susceptible |
| 28–319 | Jun 2011 | MAS | Unique | ST-37 | Not availablea | Trunc158–430 | None | Susceptible |
| 1–873 | Dec 2004 | BOL | Unique | Novel ST | None | None | None | Inducible resistance |
Sequence clade, MLST types, erm(41) mutations, and rrl mutations were all deduced from the genome sequencing data.
Abbreviations: ABS, Mycobacterium abscessus subsp abscessus; BOL, Mycobacterium abscessus subsp bolletii; MAS, Mycobacterium abscessus subsp massiliense; MLST, multilocus sequence type; ST, sequence type; VNTR, variable-number tandem repeat.
a Insufficient sequence reads to determine sequence clade.